ESC 365 - How low can early introduction of evidence based heart failure medications drive readmission rates?

HFA Premium Access

How low can early introduction of evidence based heart failure medications drive readmission rates?

Session: ePosters in chronic heart failure - pharmacotherapy 3

Topic: Pharmacotherapy

Speaker: Doctor T. Caspi (London, GB)

Event: Heart Failure 2023

Congress Presentation

Add to my library

About the speaker

Doctor Talia Caspi

Homerton University Hospital, London (United Kingdom of Great Britain & Northern Ireland)

0 follower

6 more presentations in this session

Heart rate management practices in HFrEF among Indian cardiologists: Role of beta-blocker and ivabradine-based therapy

Speaker: Doctor V. Kolapkar (Mumbai, IN)

Myocardial ketone body oxidation underlies the salutary effects of SGLT2 inhibitor treatment in heart failure

Speaker: Ms S. Voorrips (Groningen, NL)

The effect of add-on Ivabradine in patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials and real-world data

Speaker: Doctor C. Liao (Tainan, TW)

How much can ejection fraction be improved in patients with heart failure with reduced ejection fraction (HFrEF) by the early introduction of evidence-based heart failure medication?

Speaker: Doctor J. White (London, GB)

Early treatment of heart failure: a non-interventional observational study programme of patients with heart failure and initiated on dapagliflozin (EVOLUTION HF)

Speaker: Doctor S. Adamsson Eryd (SE)

Access the full session

ePosters in chronic heart failure - pharmacotherapy 3

Speakers: Doctor T. Caspi, Doctor V. Kolapkar, Ms S. Voorrips, Doctor C. Liao, Doctor J. White...

About the event

Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources